Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sunil Sharma

Showing results (391-400 of 429) with videos related to

Pageof 43
Sort By:
The Lancet. Infectious Diseases|March 5, 2022
Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection studyBridget E Barber, Melissa Fernandez, Hardik Babubhai Patel, et al.
BMC Cancer|May 7, 2021
A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarkerKristen C Kelley, Kenneth F Grossman, Mary Brittain-Blankenship, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2011
Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumorsGeoffrey I Shapiro, Raoul Tibes, Michael S Gordon, et al.
The New England Journal of Medicine|March 28, 2014
Ceritinib in ALK-rearranged non-small-cell lung cancerAlice T Shaw, Dong-Wan Kim, Ranee Mehra, et al.
Blood|February 19, 2020
Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitorsDyana T Saenz, Warren Fiskus, Christopher P Mill, et al.
Molecular Cancer Therapeutics|December 14, 2002
Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-IRobert B Lobell, Dongming Liu, Carolyn A Buser, et al.
Leukemia|December 22, 2018
Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AMLDyana T Saenz, Warren Fiskus, Taghi Manshouri, et al.
The Oncologist|June 10, 2026
A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM) and paricalcitol as neoadjuvant therapy in pancreatic cancerAlexa F Viniotis, Gayle S Jameson, Betsy C Wertheim, et al.
The Journal of Arthroplasty|November 1, 2025
2025 ICM: Use of Newer Antibiotics and Fluoroquinolone-ResistanceFouad Z Sadek, Staffan Tevell, Jaime Lora-Tamayo, et al.
Cancer Discovery|April 2, 2017
A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic <i>BRAF</i>-Mutant Colorectal CancerRobin M J M van Geel, Josep Tabernero, Elena Elez, et al.
Pageof 43

Showing results (391-400 of 429) with videos related to

Sort By:
Pageof 43
The Lancet. Infectious Diseases|March 5, 2022
Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection studyBridget E Barber, Melissa Fernandez, Hardik Babubhai Patel, et al.
BMC Cancer|May 7, 2021
A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarkerKristen C Kelley, Kenneth F Grossman, Mary Brittain-Blankenship, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2011
Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumorsGeoffrey I Shapiro, Raoul Tibes, Michael S Gordon, et al.
The New England Journal of Medicine|March 28, 2014
Ceritinib in ALK-rearranged non-small-cell lung cancerAlice T Shaw, Dong-Wan Kim, Ranee Mehra, et al.
Blood|February 19, 2020
Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitorsDyana T Saenz, Warren Fiskus, Christopher P Mill, et al.
Molecular Cancer Therapeutics|December 14, 2002
Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-IRobert B Lobell, Dongming Liu, Carolyn A Buser, et al.
Leukemia|December 22, 2018
Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AMLDyana T Saenz, Warren Fiskus, Taghi Manshouri, et al.
The Oncologist|June 10, 2026
A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM) and paricalcitol as neoadjuvant therapy in pancreatic cancerAlexa F Viniotis, Gayle S Jameson, Betsy C Wertheim, et al.
The Journal of Arthroplasty|November 1, 2025
2025 ICM: Use of Newer Antibiotics and Fluoroquinolone-ResistanceFouad Z Sadek, Staffan Tevell, Jaime Lora-Tamayo, et al.
Cancer Discovery|April 2, 2017
A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic <i>BRAF</i>-Mutant Colorectal CancerRobin M J M van Geel, Josep Tabernero, Elena Elez, et al.
Pageof 43